Clinical Trials Sponsored by Travere Therapeutics, Inc.

Total 2945 results

Travere Therapeutics, Inc.

Recruiting

A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment (HARMONY)

Homocystinuria

United States
Travere Therapeutics, Inc.

Recruiting

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN (SPARTACUS)

Immunoglobulin A Nephropathy

United States, Hong Kong
Travere Therapeutics, Inc.

Active, not recruiting

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)

Immunoglobulin A Nephropathy

United States, Australia, Belgium, Croatia, Czechia, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom
Travere Therapeutics, Inc.

Completed

Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension

Healthy Subjects

United Kingdom
Travere Therapeutics, Inc.

Active, not recruiting

Pegtibatinase as an Enzyme Therapy for Patients With Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)

Homocystinuria

United States
Travere Therapeutics, Inc.

Active, not recruiting

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX)

Focal Segmental Glomerulosclerosis

United States, Australia, Belgium, Croatia, Estonia, Germany, Hong Kong, Italy, Korea, Republic of, Poland, Portugal, Spain, Taiwan, United Kingdom, Argentina, Brazil, Canada, Czechia, Denmark, France, New Zealand, Sweden
Travere Therapeutics, Inc.

Terminated

Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants (PKAN)

Pantothenate Kinase-Associated Neurodegeneration

United States, Canada, Czechia, France, Germany, Italy, Norway, Poland, Spain
Travere Therapeutics, Inc.

Unknown

Cerebrotendinous Xanthomatosis (CTX) Prevalence Study

Cerebrotendinous Xanthomatosis (CTX)

United States
Travere Therapeutics, Inc.

Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (EPPIK)

Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | Minimal Change Disease | Alport Syndrome | IgA Vasculitis

United States, Italy, Netherlands, Poland, Spain, United Kingdom, Germany, Sweden
Travere Therapeutics, Inc.

Recruiting

Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)

Homocystinuria Due to CBS Deficiency

Ireland, Qatar, United States, United Kingdom
Travere Therapeutics, Inc.

Completed

Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) (HONUS)

Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy

United States, Spain, Germany
Travere Therapeutics, Inc.

Active, not recruiting

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis (DUET)

Focal Segmental Glomerulosclerosis

United States, Italy, Czechia
University of Edinburgh
Travere Therapeutics, Inc.

Recruiting

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) (SPARVASC)

Cardiovascular Diseases | Kidney Diseases | ANCA Associated Vasculitis

United Kingdom
Tacere Therapeutics, Inc.

Terminated

Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.

Hepatitis C

United States
Tacere Therapeutics, Inc.

Completed

Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C

Hepatitis C

United States
University of Leicester
Travere Therapeutics, Inc.

Active, not recruiting

A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy (SPARTAN)

Immune System Diseases | Autoimmune Diseases | Kidney Diseases | Glomerulonephritis | Immunoglobulin A Nephropathy | Glomerulonephritis, IGA

United Kingdom
Travera Inc
xCures

Recruiting

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (TraveraRTGx)

Melanoma | Carcinoma, Renal Cell | Carcinoma | Carcinoma, Non-Small-Cell Lung | Carcinoma, Hepatocellular | Carcinoma, Pancreatic | Pancreatic Cancer | Mesothelioma | Cholangiocarcinoma | Carcinoma, Neuroendocrine | Carcinoma, Small Cell | Pleural Effusion, Malignant | Carcinoma, Pancreatic Ductal | Carcinoma of the... and other conditions

United States
Travera Inc
John B. Amos Cancer Center

Not yet recruiting

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Carcinoma, Renal Cell | Carcinoma | Carcinoma, Non-Small-Cell Lung | Carcinoma, Hepatocellular | Carcinoma, Pancreatic | Mesothelioma | AML | Cholangiocarcinoma | Stage IV Lung Cancer | Carcinoma, Neuroendocrine | Stage IV Breast Cancer | Carcinoma, Ductal | Malignant Ascites | Carcinoma Prostate | Stage III Breast Cancer and other conditions

United States
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States
Sirion Therapeutics, Inc.
ReVision Therapeutics, Inc.

Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Geographic Atrophy | Dry Age Related Macular Degeneration
Therapeutics, Inc.

Completed

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

Tinea Pedis

United States, Puerto Rico
Therapeutics, Inc.

Completed

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

Plaque Psoriasis

United States, Georgia, Ukraine
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (305)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Tinea Pedis | Tinea Cruris

United States
Therapeutics, Inc.

Completed

A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis

Scalp Psoriasis

United States
Therapeutics, Inc.

Completed

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Acne Vulgaris

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

Plaque Psoriasis

United States
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With IgA Nephropathy (ALIGN)

Immunoglobulin A Nephropathy | IgA Nephropathy

United States, Spain, Canada, Taiwan, Hong Kong, China, New Zealand, United Kingdom, Korea, Republic of, Australia, Germany, France, India, Japan, Czechia, Argentina, Italy, Colombia, Ireland, Brazil, Poland, Portugal
Millendo Therapeutics US, Inc.

Terminated

Nevanimibe HCl for the Treatment of Classic CAH

Congenital Adrenal Hyperplasia

Spain, Israel, France, Brazil, Czechia
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

Diabetic Kidney Disease | Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | IgA Nephropathy | Diabetic Nephropathy Type 2 | Alport Syndrome

United States, Spain, Korea, Republic of, Australia, Italy, United Kingdom
Millendo Therapeutics US, Inc.

Terminated

A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

Cushing Syndrome

United States, United Kingdom
Cascadian Therapeutics Inc.
Celldex Therapeutics

Completed

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

Advanced Breast Carcinoma | Advanced Ovarian Carcinoma

United States
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Eikon Therapeutics
Impact Therapeutics, Inc.

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Australia, United States
ImmuneOncia Therapeutics Inc.

Not yet recruiting

A Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (TMB-H)

TMB-H | Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
Axsome Therapeutics, Inc.

Recruiting

Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol (PARADIGM)

Major Depressive Disorder

United States
Actym Therapeutics, Inc.

Not yet recruiting

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Solid Tumor

Australia
Nested Therapeutics, Inc

Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628)

Glioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene Mutation

Australia
Viracta Therapeutics, Inc.

Recruiting

A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Advanced Cancer

Spain
Biora Therapeutics, Inc.

Recruiting

BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

Healthy

United States

Clinical Trials Sponsored by Travere Therapeutics, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations